Pharma Websites and Digital Marketing: What’s Allowed, What’s Not

Pharmaceutical marketing in the US is legal, heavily regulated, and unlike any other industry. The FDA’s Office of Prescription Drug Promotion (OPDP) governs every public claim about a prescription drug, from a TV spot to a sponsored tweet, and the rules around “fair balance,” Important Safety Information (ISI), and adverse-event reporting carry real legal teeth. If you are a pharma or biotech marketer, a startup founder in digital health, or an agency team picking up your first drug brand, this piece is a practical map of what the regulations require, how they differ globally, and where enforcement has recently intensified.

Disclaimer: This article is B2B guidance for marketing, product, and compliance teams. It is not legal advice. Compliance specifics for your product, claims, and distribution channel should always be confirmed with qualified regulatory counsel and your MLR (medical/legal/regulatory) team.

Why DTC Pharma Advertising Exists in the US at All

Most people in other countries are genuinely surprised to hear that the US allows pharmaceutical companies to run prime-time TV ads for prescription drugs. The United States and New Zealand are the only two countries in the world that permit direct-to-consumer advertising of prescription medicines. Every other high-income nation prohibits it.

The philosophical gap is not just cultural. It is a deliberate regulatory choice that divides two different theories about where prescribing decisions should originate.

The US model (FDA, since 1997): DTC advertising is permitted, provided companies present benefit and risk information in a “fair balance.” The FDA’s view is that informed patients can be active participants in their care decisions. The agency focuses on disclosure standards rather than prohibitions.

The EU and UK model: Under Article 88(1) of EU Directive 2001/83/EC, all EU member states must prohibit advertising of prescription-only medicines (POMs) to the general public. The UK maintains the same absolute prohibition under Regulation 284 of the Human Medicines Regulations 2012 and Rule 12.12 of the CAP Code, with criminal liability for violators. The European framework holds that prescribing decisions should remain insulated from consumer persuasion, full stop.

The commercial stakes of the US exception are enormous. The top 10 US pharma companies collectively spent $13.8 billion on advertising and promotion in 2023 alone. DTC television advertising exceeded $6 billion in 2024, with immunology brands alone accounting for roughly one-third of that spend. Across the decade from 2020 to 2024, the industry spent just under $50 billion on TV drug advertising. These figures are a live policy flashpoint: the FDA Commissioner has publicly stated this money would be better spent lowering drug prices, and Congress is actively debating restrictions.

The Core US Regulatory Framework: Fair Balance and the Major Statement

The primary legal text is 21 CFR Part 202, which governs all prescription drug advertising in the US. Two concepts sit at the center of every compliance decision.

What Is “Fair Balance”?

Fair balance is not a vague aspiration. Under 21 CFR 202.1 and Section 502(n) of the Federal Food, Drug, and Cosmetic Act (FDCA), every prescription drug advertisement that makes a product claim must present risk and benefit information with “comparable prominence and readability.” If a piece communicates a benefit, it must present the associated risks with equal weight. This applies to display ads, websites, brochures, sales rep leave-behinds, and broadcast media alike.

In practice, fair balance means:

• Risk information must occupy comparable space (in print) or comparable time (in broadcast) to benefit information.
• The typeface and legibility of risk disclosures must match that used for benefit claims.
• You cannot use a visually loud, full-color benefit claim alongside a small-print, low-contrast risk summary.

What Is the “Major Statement” Rule for Broadcast Ads?

For TV and radio ads that present both the name of a drug and its indication, the law requires a “major statement” disclosing the drug’s most important risks. In November 2023, the FDA finalized a rule (published at 88 FR 80958) that took effect on November 20, 2024, after 16 years of rulemaking. The rule establishes five specific requirements for how the major statement must be delivered:

1. Consumer-friendly language: Risk information must be written so a general audience can understand it, not in technical clinical language.
2. Dual modality: For TV, the major statement must be presented simultaneously in both audio and on-screen text.
3. No distracting elements: Visual or audio elements that draw attention away from the risk disclosure during the major statement are prohibited.
4. Sufficient audio volume: The spoken risk disclosure must be at a volume and pace comparable to the rest of the ad.
5. Readable text: On-screen text must meet minimum size and contrast requirements.

This 2024 rule changed what “compliant” looks like for every pharma TV ad currently in rotation.

Important Safety Information (ISI) on Websites and Digital Ads

ISI is the standardized risk disclosure block that appears on pharma brand websites, digital ads, and print materials. It is not a formal regulatory term in the CFR, but it is the industry-standard implementation of the fair balance and brief summary obligations under 21 CFR 202.1.

On a brand website, ISI typically appears:

• As a persistent sticky footer or above-the-fold anchor on any page that makes a product claim.
• In a collapsible “Important Safety Information” section that is visible without requiring a click to find it.
• With a link to the full Prescribing Information (PI) or Patient Information Leaflet for complete risk detail.

A compliant pharma brand website cannot bury ISI three scrolls below a benefit claim. The principle is that a user who encounters the benefit must encounter the risk with equivalent ease.

The One-Click Rule for Social Media and Paid Search

Social media platforms and paid search create a structural problem for fair balance: there is not enough space to present complete risk information alongside a product claim. The FDA’s 2014 guidance on internet and social media platforms with character space limitations addresses this directly.

The one-click rule permits a company to abbreviate risk disclosure to the most serious risks in a space-limited format, provided:

• A direct hyperlink is included that leads to a page devoted exclusively to complete risk information.
• The landing page cannot be the brand homepage. It must be a dedicated risk-information page.
• The hyperlink must be prominently labeled (something like “See Important Safety Information at [URL]”).

This guidance applies to sponsored search ads, Twitter/X posts, and any other format where the physical character limit makes full ISI impossible. It does not give permission to omit risk information entirely. The link is not optional.

Adverse-Event Reporting Obligations: Social Media Is Not Safe Harbor

One of the most underestimated compliance obligations in pharma digital marketing is adverse-event (AE) reporting. Under 21 CFR 314.80, pharmaceutical applicants must report any serious and unexpected adverse drug experience within 15 calendar days of first receipt anywhere within the company.

The trigger is not when headquarters processes the report. It is when anyone at the company, including a field rep, a medical affairs employee, or a social media manager monitoring influencer comments, first becomes aware of the information.

This has concrete implications for pharma digital marketing teams:

• If an influencer posts about your drug and a follower comments describing a serious unexpected side effect, that comment can start the 15-day clock the moment a company employee sees it.
• Social media listening tools that flag brand mentions are, by extension, part of your pharmacovigilance infrastructure.
• Standard operating procedures must define who reviews social comments, how fast, and how they escalate potential AE reports to pharmacovigilance.

Running an influencer campaign without documented AE intake procedures is not a marketing oversight. It is a regulatory compliance gap.

MLR Review: The Internal Gate Between Idea and Publication

MLR (medical/legal/regulatory) review is the internal approval workflow that sits between any promotional idea and its public release. It is not mandated by the CFR as a named procedure, but it is the practical mechanism by which pharma companies ensure compliance before materials go live.

A standard MLR process involves:

• Medical review: Every clinical claim is reviewed by a medical or clinical affairs lead for scientific accuracy and substantiation against approved labeling.
• Legal review: Intellectual property, liability exposure, and any claims that could imply off-label use are flagged and resolved.
• Regulatory review: The material is checked against 21 CFR Part 202, fair balance requirements, ISI completeness, and any OPDP guidance relevant to the format.

Typical MLR timelines by format:

Note: The FDA does not require pre-approval of prescription drug advertisements before dissemination, but companies must submit all promotional materials to OPDP upon initial dissemination. A voluntary pre-review program exists with a 45-day target turnaround for materials submitted before launch. Most large pharma companies use this program for major campaigns to reduce enforcement risk.

What Pharma Marketers Can and Cannot Do: A Quick Reference Table

Influencers and Enforcement: What Changed in 2024-2025

In 2024, FDA’s OPDP issued only 5 untitled letters and 0 warning letters for the entire year, a historically low enforcement volume. Three of those five letters involved social media influencers, including an Instagram post by Brittany Mahomes for AUVI-Q, flagging influencer marketing as the primary enforcement focus even at low total volume.

That changed sharply in 2025. Following a September 9, 2025 presidential memorandum directing HHS and FDA to enforce FDCA prescription drug advertising provisions more aggressively, FDA issued approximately 100 enforcement letters in September 2025 alone and stated it expects to issue “hundreds of enforcement letters each year” if industry behavior does not change. The FDA also announced AI-assisted surveillance of pharmaceutical social media.

This is a materially different enforcement environment from anything pharma marketing teams operated under before 2025. Pharma marketers, agency partners, and influencer talent managers working with drug brands should treat the pre-2025 era of low enforcement volume as historical, not predictive.

How This Fits Into a Broader Healthcare Website Strategy

The FDA compliance obligations described here are a subset of the broader discipline required for any regulated healthcare web presence. Pharma brand sites, HCP portals, patient support platforms, and DTC product pages all sit within a web of overlapping requirements: HIPAA for patient data, 21 CFR Part 11 for electronic records in some contexts, and OPDP rules for promotional claims. For a broader look at how these obligations interact with site architecture, accessibility, and content strategy, see our guide to healthcare website design.

We have worked with digital health founders and regulated marketing teams who assumed that building a compliant pharma web presence was primarily a copy-editing exercise. In practice, it requires decisions that touch information architecture (where does ISI appear, and at what scroll depth?), technical implementation (is the “Important Safety Information” section indexed differently by crawlers than the benefit claims?), and operations (who owns the process for updating ISI when labeling changes?).

Frequently Asked Questions

What are the FDA rules for pharmaceutical advertising in the US?

The primary rules are in 21 CFR Part 202 and Section 502(n) of the FDCA. Every prescription drug ad that makes a product claim must present risk and benefit information with comparable prominence (fair balance), include the major statement of key risks, and submit materials to OPDP upon initial dissemination. The FDA does not pre-clear ads, but a voluntary review program exists with a 45-day target turnaround.

What is “fair balance” in drug advertising and what does it require?

Fair balance requires that risk information be presented with the same prominence, space, and readability as benefit information. In broadcast media, the major statement must now be delivered in consumer-friendly language with simultaneous audio and on-screen text, at comparable volume and pace to benefit claims, per the FDA’s rule that took effect November 20, 2024. Fair balance is codified at 21 CFR 202.1, not just industry convention.

Why is direct-to-consumer drug advertising banned in Europe but legal in the US?

The EU prohibits DTC prescription drug advertising under Article 88(1) of Directive 2001/83/EC, on the principle that prescribing should remain insulated from consumer persuasion. The UK maintains the same prohibition under Regulation 284 of the Human Medicines Regulations 2012. The US FDA, by contrast, permits DTC advertising on the theory that informed patients can be active participants in care decisions, provided companies meet disclosure standards. The US and New Zealand are the only two countries globally that allow it.

What is the “one-click rule” for pharma social media ads?

The FDA’s 2014 guidance on character-space-limited platforms permits pharma companies to abbreviate risk disclosure in formats like sponsored tweets or paid search ads, provided they include a direct hyperlink to a page devoted exclusively to complete risk information. The link must be prominently labeled, and the destination must be a dedicated risk page, not the brand homepage.

Do pharmaceutical companies have to report adverse events found on social media?

Yes. Under 21 CFR 314.80, serious unexpected adverse events must be reported to FDA within 15 calendar days of initial receipt anywhere in the company. If a company employee, including a social media manager, sees a comment describing a serious unexpected side effect under an influencer post, that can start the reporting clock immediately. Social media monitoring programs are part of pharmacovigilance infrastructure for any drug brand running digital or influencer campaigns.

What is an MLR review in pharma marketing and how long does it take?

MLR (medical/legal/regulatory) review is the internal approval process that vets promotional materials for scientific accuracy, legal risk, and FDA compliance before publication. It is not named as a required procedure in the CFR, but it is the industry’s standard compliance gate. Timelines range from 2-5 business days for a paid search text ad to 28-45 business days for a TV spot, depending on format complexity and the organization’s internal workflow.

Can pharmaceutical companies use influencers to promote prescription drugs?

In the US, yes, but all standard pharma promotion rules apply. The influencer must disclose the commercial relationship (FTC endorsement rules), the content must include ISI or a one-click link to complete risk information, and any serious adverse events surfaced through the influencer’s comments must be captured in the company’s pharmacovigilance process. Three of the five OPDP enforcement letters issued in 2024 targeted influencer posts, and FDA has announced AI-assisted social media surveillance as of September 2025. The EU and UK prohibit this activity entirely.

Working With a Technical Team That Understands Regulated Marketing

Pharma and biotech marketing teams often discover mid-build that their agency or development vendor has no familiarity with OPDP requirements, ISI placement obligations, or the operational workflows that support pharmacovigilance on social channels. The result is a website or campaign that looks complete but requires extensive rework before legal sign-off.

At Sparkable, we work with regulated healthcare clients on the technical architecture, compliance workflows, and content infrastructure that makes these projects go smoothly. We are not your regulatory counsel, but we are the team that has already navigated HIPAA-compliant data flows, MLR-ready content management systems, and the specific UX patterns that satisfy fair balance without making a brand site unusable.

If you are building a pharma brand site, a DTC digital campaign infrastructure, or an HCP portal and want a technical partner who understands the compliance layer before the first line of code is written, book a free consultation with the Sparkable team. No sales pitch, just a direct conversation about what you are building and whether we are a fit.